Ignite Creation Date:
2024-05-05 @ 5:27 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00464646
Status:
COMPLETED
Last Update Posted:
2021-10-25
First Post:
2007-04-19
Brief Title:
Therapy With Bevacizumab BEV Epirubicin and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer
Sponsor:
NSABP Foundation Inc
Organization:
NSABP Foundation Inc
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Breast Cancer |